Johnson & Johnson reported positive survival rates and treatment outcomes using the Impella device in high-risk percutaneous coronary intervention.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.